Direct effect of GLP-1 infusion on endogenous glucose production in humans
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis Glucagon-like peptide-1 (GLP-1) lowers glucose levels by potentiating glucose-induced insulin secretion and inhibiting glucagon release. The question of whether GLP-1 exerts direct effects on the liver, independently of the hormonal changes, is controversial. We tested whether an exogenous GLP-1 infusion, designed to achieve physiological postprandial levels, directly affects endogenous glucose production (EGP) under conditions mimicking the fasting state in diabetes.Methods In 14 healthy volunteers, we applied the pancreatic clamp technique, whereby plasma insulin and glucagon levels are clamped using somatostatin and hormone replacement. The clamp was applied in paired, 4 h experiments, during which saline (control) or GLP-1(7-37)amide (0.4 pmol min⁻¹ kg⁻¹) was infused.Results During the control study, plasma insulin and glucagon were maintained at basal levels and plasma C-peptide was suppressed, such that plasma glucose rose to a plateau of ~10.5 mmol/l and tracer-determined EGP increased by ~60%. During GLP-1 infusion at matched plasma glucose levels, the rise of EGP from baseline was fully prevented. Lipolysis (as indexed by NEFA concentrations and tracer-determined glycerol rate of appearance) and substrate utilisation (by indirect calorimetry) were similar between control and GLP-1 infusion.Conclusions/interpretation GLP-1 inhibits EGP under conditions where plasma insulin and glucagon are not allowed to change and glucose concentrations are matched, indicating either a direct effect on hepatocytes or neurally mediated inhibition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, infusion of native GLP-1 showed acute effects on glucose metabolism by reducing hepatic glucose production [167,168].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [168]
In the citing paper
“Native GLP-1 did not change free fatty acid (FFA) concentrations or glycerol rate of appearance [168].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [168]
In the citing paper
“Several studies have shown an improvement in hepatic glucose and lipid metabolism after GLP-1 injection [167,168] or GLP-1RA treatment [24,102,169,170,171] either in humans and animal studies.”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [168]
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 1×
“The classical physiological actions of glucagon-like peptide-1 (GLP-1) include potentiation of glucose-induced insulin secretion, suppression of glucagon release, inhibition of gastric emptying and enhancement of satiety [1].”
BackgroundThe theoretical bases of indirect calorimetry: A review
Ferrannini, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90110-2 · Cited by 1,580 · cited 1×
“Substrate oxidation rates were calculated from gas exchange measurements as described [23].”
MethodSelf-citationMeasurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816 · cited 1×
“After starting SRIF infusion, the total glucose and glycerol Ra were calculated using Steele’s equation, as previously described [22].”
MethodGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 1×
“GLP-1 receptors were originally not found in human liver [2].”
BackgroundSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Self-citationØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Vahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0153 · Cited by 318 · cited 1×
“GLP-1 receptor mRNA has also been described in neurons in the hepatic portal region [7].”
BackgroundKnauf, C. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25764 · Cited by 308 · cited 1×
“Finally, intracerebroventricular GLP-1 administration in mice [18] and peripheral GLP-1 infusions in man [19] increased sympathetic activity.”
BackgroundVagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1
Nakabayashi, H., Nishizawa, M., Nakagawa, A., Takeda, R., & Niijima, A. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.5.e808 · Cited by 204
Prigeon, R. L., Quddusi, S., Paty, B., & D'Alessio, D. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2003 · Cited by 199 · cited 3×
“The only previous study that is indicative of a direct effect of GLP-1 on EGP [12] was carried out in eight healthy volunteers, who did not receive a saline infusion control study.”
BackgroundResultInfluentialHvidberg, A., Nielsen, M. T., Hilsted, J., Ørskov, C., & Holst, J. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90164-3 · Cited by 195 · cited 2×
“With regard to the effects on whole-body glucose disposal, early studies [8, 11] found no direct effect of GLP-1, i.”
BackgroundGlucagon-Like Peptide-1 Augments Insulin-Mediated Glucose Uptake in the Obese State
Egan, J. M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.8.3768 · Cited by 119 · cited 1×
“Subsequent work, however, reported an independent effect of GLP-1 on the promotion of glucose disposal in non-diabetic [13], obese [14] or diabetic participants [15].”
BackgroundVella, A., Shah, P., Basu, R., Basu, A., Holst, J. J., & Rizza, R. A. (2000) · Diabetes · doi:10.2337/diabetes.49.4.611 · Cited by 119 · cited 1×
“Previous reports [11, 24] that failed to observe a direct inhibitory effect of GLP-1 on EGP under pancreatic clamp conditions can probably be explained by their use of high insulin replacement doses, which suppressed EGP completely [11] or by greater than 75% [24] in the control studies, thereby leaving little room fo…”
ResultLARSSON, H., HOLST, J. J., & AHRÉN, B. (1997) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.1997.00161.x · Cited by 114 · cited 2×
“Likewise, others [9, 10] reported that the effects of GLP-1 on EGP and glucose disposal were abolished when co-infusing somatotropin release-inhibiting factor (SRIF), thereby blocking the insulin and glucagon response to GLP-1.”
BackgroundResultAyala, J. E., Bracy, D. P., James, F. D., Julien, B. M., Wasserman, D. H., & Drucker, D. J. (2009) · Endocrinology · doi:10.1210/en.2008-0945 · Cited by 114 · cited 1×
“Thus, in insulin clamp experiments in GLP-1 receptor knockout mice, insulin suppression of EGP was impaired and animals became hyperglycaemic during exercise [27].”
BackgroundTomás, E., Stanojevic, V., & Habener, J. F. (2011) · Regulatory Peptides · doi:10.1016/j.regpep.2011.01.003 · Cited by 107 · cited 1×
“Alternatively, the GLP-1(28– 36)amide nonapeptide, which enters hepatocytes independently of the GLP-1 receptor, may have suppressed glucose production, as shown in mouse hepatocytes [26].”
BackgroundToft-Nielson, M.-B., Madsbad, S., & Holst, J. J. (1996) · Diabetes · doi:10.2337/diab.45.5.552 · Cited by 105 · cited 2×
“Likewise, others [9, 10] reported that the effects of GLP-1 on EGP and glucose disposal were abolished when co-infusing somatotropin release-inhibiting factor (SRIF), thereby blocking the insulin and glucagon response to GLP-1.”
BackgroundResultMechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes
Muscelli, E., Casolaro, A., Gastaldelli, A., Mari, A., Seghieri, G., Astiarraga, B., Chen, Y., Alba, M., Holst, J., & Ferrannini, E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1205 · Cited by 104 · cited 1×
“4 pmolminkg), while the plasma glucose profile of the first study was closely reproduced through a variable intravenous glucose infusion, using an algorithm developed ad hoc [20].”
MethodSelf-citationBharucha, A. E., Charkoudian, N., Andrews, C. N., Camilleri, M., Sletten, D., Zinsmeister, A. R., & Low, P. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2008 · Cited by 98 · cited 1×
“Finally, intracerebroventricular GLP-1 administration in mice [18] and peripheral GLP-1 infusions in man [19] increased sympathetic activity.”
BackgroundBertin, E., Arner, P., Bolinder, J., & Hagström-Toft, E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7330 · Cited by 83 · cited 1×
“In contrast, using in situ microdialysis and local GLP-1 perfusion, Bertin et al [17] detected no change in lipolysis or blood flow in adipose tissue or muscle.”
ResultAssessment of methods for improving tracer estimation of non-steady-state rate of appearance
Gastaldelli, A., Coggan, A. R., & Wolfe, R. R. (1999) · Journal of Applied Physiology · doi:10.1152/jappl.1999.87.5.1813 · Cited by 69 · cited 1×
“The tracer enrichment of 6,6-[(2)H2] glucose and [(2)H5]glycerol was measured by gas chromatography/mass spectrometry as previously described [21].”
MethodSelf-citationØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diabetes.42.5.658 · Cited by 68
Meneilly, G. S., McIntosh, C. H. S., Pederson, R. A., Habener, J. F., Gingerich, R., Egan, J. M., Finegood, D. T., & Elahi, D. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1951 · Cited by 63 · cited 2×
“However, we cannot rule out the possibility that pharmacological doses of GLP-1 such as those used in previous studies [14–25] may promote whole-body glucose uptake.”
BackgroundResultBertin, É. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.3.1229 · Cited by 57
Wang, Y., Kole, H., Montrose-Rafizadeh, C., Perfetti, R., Bernier, M., & Egan, J. (1997) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0190241 · Cited by 54
Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects
Sancho, V., Trigo, M., Martín-Duce, A., González, N., Acitores, A., Arnés, L., Valverde, I., Malaisse, W., & Villanueva-Peñacarrillo, M. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.17.6.1133 · Cited by 53 · cited 1×
“Although GLP-1 receptors are not produced in adipocytes, the peptide appeared to stimulate lipolysis in fat cells from obese participants [16].”
BackgroundVella, A., Shah, P., Basu, R., Basu, A., Camilleri, M., Schwenk, F. W., Holst, J. J., & Rizza, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.3.565 · Cited by 48 · cited 1×
“However, we cannot rule out the possibility that pharmacological doses of GLP-1 such as those used in previous studies [14–25] may promote whole-body glucose uptake.”
ResultJohnson, K. M. S., Edgerton, D. S., Rodewald, T., Scott, M., Farmer, B., Neal, D., & Cherrington, A. D. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00275.2007 · Cited by 46 · cited 2×
“In catheterised dogs, Johnson et al [29] found that direct infusion of GLP-1 into the portal vein at matched plasma glucose, insulin and glucagon concentrations resulted in a more positive net hepatic glucose balance, which is the net sum of EGP and hepatic glucose uptake.”
BackgroundCharacteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients
Villanueva‐Peñacarrillo, M. L., Martín‐Duce, A., Ramos-Álvarez, I., Gutiérrez-Rojas, I., Moreno, P., Nuche‐Berenguer, B., Acitores, A., Sancho, V., Valverde, I., & González, N. (2011) · Regulatory Peptides · doi:10.1016/j.regpep.2011.03.002 · Cited by 31
Toft-Nielson, M., Madsbad, S., & Holst, J. J. (1996) · Diabetes · doi:10.2337/diabetes.45.5.552 · Cited by 30
Shalev, A., Ninnis, R., & Keller, U. (1998) · Hormone Research in Paediatrics · doi:10.1159/000023175 · Cited by 24
Cited by
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“2 hr pancreatic clamp where plasma insulin levels were maintained at concentrations that do not suppress EGP ( 25 pM) (Seghieri et al., 2013), demonstrating that GLP-1 can inhibit hepatic glucose production independent of changes in insulin and glucagon.”
BackgroundIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
“In addition, GLP-1 appears to reduce hepatic glucose output even independent of changes in plasma glucagon.(28) Since the liver does not appear to be equipped with GLP-1 receptors, this has to be mediated indirectly, for example, through the autonomic nervous system.”
BackgroundSelf-citationLipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
“presumably through binding to hepatic GLP-1 receptors and/or mediated by the central/peripheral nervous system [115, 119-122].”
BackgroundNonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“GLP1 analogs may also act to decrease hepatic glucose production (Seghieri et al., 2013) and possibly decrease hepatic DNL (Armstrong et al., 2016).”
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Metadata
- Authors
- Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B. D., Casolaro, A., Barsotti, E., Pocai, A., Nauck, M., Muscelli, E., & Ferrannini, E.
- Affiliations
- University of Pisa (IT)
- Istituto di Fisiologia Clinica (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Diabeteszentrum Bad Lauterberg (DE)
- Corresponding author
- Ferrannini, E.
- ORCID
- Venue
- Diabetologia
- Published
- 2012-10-12
- Volume
- 56
- Issue
- 1
- Pages
- 156-161
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1978334327
- Cited by
- 143
- References
- 30
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 13 · 2023: 7 · 2022: 8 · 2021: 13 · 2020: 8 · 2019: 13 · 2018: 8 · 2017: 11 · 2016: 15 · 2015: 18 · 2014: 11 · 2013: 10
- FWCI
- 10.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, endogenous glucose production, hepatic glucose production, glucagon, fasting state, diabetes mellitus, lipolysis, substrate utilization, hepatocytes
- MeSH terms
- Adult, Blood Glucose, Calorimetry, Indirect, Fatty Acids, Nonesterified, Female, Gluconeogenesis, Glucose, Glycerol, Humans, Hypoglycemic Agents, Infusions, Intravenous, Lipolysis, Liver, Male, Peptide Fragments, Sympathomimetics, Glucose Clamp Technique, Up-Regulation, Cross-Over Studies, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.